GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome...
Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (OTC: HMLSF), the world’s first and still only cannabis ETF, has adjusted its portfolio this month as its benchmark, the North...
In contrast to a period when promotion and fluff have grabbed the attention of novice stock investors interested in the legal cannabis theme since early 2013, we are now seeing companies...
Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) (OTC: HMLSF) has been hit hard over the past two weeks, declining 8.4% since July 26th despite what has been a stable market...
GW Pharma (NASDAQ: GWPH) issued a press release after the close of trading on Monday to report its FY17-Q3 financials and provide an operational update. The most significant news...
As the U.S. cannabis industry has evolved over the past few years, so has the market for publicly-traded cannabis stocks. In 2014, very few publicly-traded companies were reporting substantial...
The first week of trading for the new Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (OTC: HMLSF) has been a tremendous success. While Tuesday saw its first decline...
Let’s face it, when it comes to cannabis stocks, Canada continues to crush the United States, where federal illegality makes it more difficult to operate and to raise capital....
GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc...
The Roland George Investments Program (RGIP), a student-managed portfolio worth $3.5 million at Stetson University in Florida, is investing in the cannabis industry. The program, headed by Dr. K.C....
Earlier this week, we highlighted a story published on Leafly regarding lobbying efforts by GW Pharma (NASDAQ: GWPH). Leafly’s Bruce Barcott discovered that GW Pharma and its U.S. subsidiary,...
GW Pharmaceuticals plc Reports First Quarter 2017 Financial Results and Operational Progress Epidiolex® NDA submission and launch preparation on track New Positive Phase 2 glioma data further demonstrates value...
GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE)...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress – Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – – NDA submission...
GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting – Presentations include clinical results from Phase 3 programs in...
The publicly-traded cannabis stocks have enjoyed an immense rally that began on 9/1, fueled by speculation regarding this week’s legalization ballot initiatives in Arizona, California, Maine, Massachusetts and Nevada along with...
Wissington glasshouse to grow plants for epilepsy medicine Wissington, Norfolk – 25 October 2016 British Sugar, the leading UK beet sugar producer, announces today that its horticultural business is...
GW Pharmaceuticals plc Announces Intention to Continue Trading Exclusively on NASDAQ and Planned Cancellation of Trading of Ordinary Shares on AIM GW remains headquartered in UK and continues to...
Goldman Sachs initiated coverage on GW Pharma (NASDAQ: GWPH) (AIM: GWP) on October 7th, with a “Buy” rating and a target of $189. The target was based on blend...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical...
Cowen and Company released an extensive report on the cannabis industry today, suggesting the recreational market could grow to $50 billion by 2026. While this isn’t the first time...
Shares in GW Pharma (NASDAQ: GWPH) (AIM: GWP) shot up in trading today after Reuters posted an exclusive report that the company has hired investment bank Morgan Stanley in...
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) – – Positive FDA pre-NDA meeting...
With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma’s (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from cannabis continues...
